Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Dyslipidaemia

Statin-associated muscle symptoms — really all in the mind?

Nature Reviews Cardiology volume 14, pages 445–446 (2017)Cite this article

Subjects

The nocebo effect might be involved in a substantial proportion of patients experiencing muscle symptoms attributed to statin therapy. This observation underlines the importance of patient counselling and physician opposition to misinformation. Nonetheless, clinicians face a reality in which many patients do not tolerate adequate statin therapy despite rigorous efforts. Novel treatment strategies are, therefore, much needed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gupta, A. et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet http://dx.doi.org/10.1016/S0140-6736(17)31075-9 (2017).

  2. Bruckert, E., Hayem, G., Dejager, S., Yau, C. & Bégaud, B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients — the PRIMO Study. Cardiovasc. Drugs Ther. 19, 403–414 (2005).

    Article  CAS  Google Scholar 

  3. Collins, R. et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532–2561 (2016).

    Article  CAS  Google Scholar 

  4. Steen, D. L., Khan, I., Ansell, D., Sanchez, R. J. & Ray, K. K. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines. BMJ Open 7, e013255 (2017).

    Article  Google Scholar 

  5. Cohen, J. D., Brinton, E. A., Ito, M. K. & Jacobson, T. A. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J. Clin. Lipidol. 6, 208–215 (2012).

    Article  Google Scholar 

  6. Serban, M.-C. et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J. Am. Coll. Cardiol. 69, 1386–1395 (2017).

    Article  CAS  Google Scholar 

  7. Nissen, S. E. et al. Efficacy and tolerability of evolocumab versus ezetimibe in patients with muscle-related statin intolerance. JAMA 315, 1580 (2016).

    Article  CAS  Google Scholar 

  8. Moriarty, P. M. et al. Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol. 9, 758–769 (2015).

    Article  Google Scholar 

  9. Stroes, E. S. et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur. Heart J. 36, 1012–1022 (2015).

    Article  CAS  Google Scholar 

  10. Rosenson, R. S. et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc. Drugs Ther. 31, 179–186 (2017).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Robert M. Stoekenbroek and John J. P. Kastelein are at the Department of Vascular Medicine, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.,

    Robert M. Stoekenbroek & John J. P. Kastelein

Authors
  1. Robert M. Stoekenbroek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John J. P. Kastelein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John J. P. Kastelein.

Ethics declarations

Competing interests

J.J.P.K. has received grants and personal fees from Amgen, Gemphire, Madrigal Pharma, Merck, Sharpe and Dohme, Sanofi/Regeneron, and The Medicines Company. R.M.S. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stoekenbroek, R., Kastelein, J. Statin-associated muscle symptoms — really all in the mind?. Nat Rev Cardiol 14, 445–446 (2017). https://doi.org/10.1038/nrcardio.2017.92

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2017.92

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing